Innoen Abeltan Plus Tablet 150/12.5 mg

Adult dose

This medication is administered once a day, regardless of meals. 1. Patients whose blood pressure is not adequately controlled by monotherapy - For patients whose blood pressure is not sufficiently controlled by irbesartan 150 mg or hydrochlorothiazide alone, administer irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily, 1 tablet. - For patients not adequately controlled on irbesartan 300 mg or irbesartan 150 mg/hydrochlorothiazide 12.5 mg, administer irbesartan 300 mg/hydrochlorothiazide 12.5 mg once daily, 1 tablet. - For patients not adequately controlled on irbesartan 300 mg/hydrochlorothiazide 12.5 mg, administer irbesartan 300 mg/hydrochlorothiazide 25 mg once daily, 1 tablet. Doses exceeding irbesartan 300 mg/hydrochlorothiazide 25 mg are not recommended. If necessary, this medication may be used in combination with other antihypertensive agents. 2. If initiating therapy for moderate to severe hypertension (stage 2), this should be individualized based on baseline blood pressure, target blood pressure, and expected increase in achieving treatment goals in comparison to monotherapy. Typically, start with irbesartan 150 mg/hydrochlorothiazide 12.5 mg once daily, and may increase to a maximum of irbesartan 300 mg/hydrochlorothiazide 25 mg after 1-2 weeks if further blood pressure control is needed. It is not recommended to use this medication for initial therapy in patients with intravascular volume depletion. ○ Patients with renal impairment Due to the hydrochlorothiazide component, this medication is not recommended for patients with severe renal impairment (creatinine clearance < 30 mL/min). Loop diuretics are preferred in this population. No dosage adjustment is necessary for renal impairment patients with creatinine clearance of ≥ 30 mL/min. ○ Patients with volume depletion If sodium and/or fluid has been lost, equilibrium must be achieved before administering this medication. ○ Patients with hepatic impairment This medication is not used in patients with severe hepatic impairment. Thiazide-type drugs should be used cautiously in patients with hepatic impairment. No dosage adjustment is necessary for patients with mild to moderate hepatic impairment. ○ Elderly patients No dosage adjustment is necessary for elderly patients. ○ Pediatrics The safety and efficacy of this medication have not been established in children and adolescents under 18 years of age.

This medication should not be administered to pregnant women or women who might become pregnant, as taking it during pregnancy may pose a risk of serious harm or death to the fetus or newborn. Do not use if there is a history of allergic reactions or hypersensitivity to the ingredients in this medication or similar medications. Administration should be avoided in patients with severely impaired kidney function or anuria. Patients with severely impaired liver function or specific liver diseases should not use this medication. Patients with a history of angioedema (swelling of the blood vessels) or those who have experienced angioedema after taking similar medications should use caution. Patients with hypotension, reduced blood volume, renal artery stenosis, kidney transplant patients, liver disease patients, and patients with heart valve disease should use this medication with caution. The diuretic component in this medication may increase sensitivity to sunlight, potentially raising the risk of skin cancer; therefore, limiting sun exposure and taking protective measures during treatment is advised. Side effects such as dizziness, fatigue, nausea, vomiting, and abnormal urination may occur, so consult a doctor if symptoms are severe. Caution is required when driving or operating machinery as dizziness or fatigue can occur. In cases of hypotension risk, it is essential to manage the loss of fluids and electrolytes due to inadequate salt intake, excessive diuretic use, diarrhea, or vomiting. Diabetic patients may be affected in terms of blood sugar control, so check blood glucose levels regularly and dosage adjustments may be necessary. Regular blood tests are needed as electrolyte imbalances (especially potassium, sodium, magnesium, etc.) may occur; caution is needed when taken alongside potassium supplements or potassium-lowering medications. Patients with a history of eye diseases such as acute angle-closure glaucoma should seek immediate treatment if vision changes or eye pain occurs after taking this medication. There may be interactions when taken with other antihypertensive medications; therefore, inform your doctor or pharmacist if you are taking any other medication. Caution against concomitant use with lithium preparations is advised due to the risk of lithium toxicity. This medication is not recommended for breastfeeding women and should not be used while nursing. Safety for children and adolescents has not been established, so the use in these populations is not recommended. For elderly patients, dosage adjustment or monitoring may be necessary due to different sensitivities. In case of overdose, symptoms of hypotension, electrolyte abnormalities, and dehydration may appear, requiring immediate medical attention.

Serious side effects

• Urticaria
• angioedema
• swelling
• jaundice
• hepatitis
• severe allergic reactions
• severe edema
• severe skin reactions
• severe allergic reactions
• urticaria

Mild side effects

• Dizziness
• fatigue
• nausea/vomiting
• abnormal urination
• increased BUN
• elevated creatine kinase
• increased creatinine
• headache
• orthostatic dizziness
• fainting

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it is best stored at room temperature between 1 and 30 degrees Celsius, avoiding extremes of temperature.

Appearance

Pink, oval, biconvex film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle